ResMed (RMD) stock is currently trading at an attractive valuation, supported by strong fundamentals including accelerating recurring revenue from its Masks & Accessories segment, high margins, and a low-debt capital structure. The company benefits from a powerful moat due to its proprietary AirView software and market share gains from a competitor’s recall. However, the investment debate is centered on the potential structural threat of GLP-1 drugs impacting its total addressable market for sleep apnea.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Is ResMed Stock A Trap Or A Missed Opportunity?
ResMed (RMD) stock is currently trading at an attractive valuation, supported by strong fundamentals including accelerating recurring revenue from its Masks & Accessories segment, high margins, and a low-debt capital structure. The company benefits from a powerful moat due to its proprietary AirView software and market share gains from a competitor’s recall. However, the investment debate is centered on the potential structural threat of GLP-1 drugs impacting its total addressable market for sleep apnea.